Stocks to sell

Bionano (NASDAQ:BNGO) is a small life sciences company. Biotech companies use Bionano’s Saphyr system for researching DNA and to diagnose illnesses caused by genetics. Up until recently, Bionano has had difficulty achieving widespread market adoption for Saphyr. However, BNGO stock has gone on a wild ride over the past year as traders gravitated to Bionano’s
0 Comments
At one point, Zomedica (NYSE:ZOM) could do no wrong. ZOM stock would explode some 2,900% from its November 2020 lows. The company was nearing commercialization of its point-of-care diagnostic product. Even the pet industry was howling about the opportunity. Source: Postmodern Studio / Shutterstock.com Nowadays, Zomedica has become a slow-motion train wreck. In fact, the last
0 Comments
In a matter of weeks, DiDi Global (NYSE:DIDI) stock has gone from a hot IPO to an undeniable disaster. Soon after its debut on the U.S. stock market at an initial price of $14 per share, the China-based ride-hailing company was hit hard by the  Chinese government’s decision to investigate and penalize it. The shares
0 Comments
A decade ago, after returning to finance from 30 years covering computer technology, I got into an argument over a company called Dendreon. You’ll see why this lingering thoughts connects me to BIIB stock below. Source: PictureDesignSwiss / Shutterstock.com Dendreon had launched a treatment for prostate cancer called Provenge. It is an immunotherapy, tied to
0 Comments
GameStop (NYSE:GME) stock has been one of 2021’s most incredible investing stories. The initial short squeeze was incredible to watch. Few market analysts could have ever imagined that a struggling mall retailer like GameStop could see its shares surge thousands of percent. Source: rblfmr / Shutterstock.com That surge, in turn, saved the company. GameStop raised
0 Comments
Other than a short-lived rally in June fueled by Reddit users, ContextLogic (NASDAQ:WISH) stock is on a permanent trajectory downward. Source: sdx15 / Shutterstock.com WISH stock peaked at $32.85, shortly after its initial public offering earlier this year. The company’s unfavorable valuations, mixed first-quarter results, and poor sales forecast continue to weigh on its share
0 Comments